Investigating how xylazine affects the toxicity of fentanyl.
Cardiorespiratory Pharmacodynamics of Fentanyl-Xylazine
This study looks at how xylazine, which is often mixed with fentanyl, affects breathing and heart function, helping us understand the risks of overdose and how it impacts blood flow and oxygen to important organs, so we can improve treatment for those who overdose.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11117169 on NIH RePORTER |
What this research studies
This research explores the effects of xylazine, a common adulterant in fentanyl, on respiratory and cardiovascular functions. It aims to understand how the combination of these substances increases the risk of overdose and impacts blood flow and oxygen delivery to vital organs. By examining the dose-response relationship and the physiological mechanisms involved, the study seeks to clarify the dangers associated with their co-administration. This knowledge could inform better treatment strategies for overdose cases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who use fentanyl and may be at risk of overdose, particularly those unknowingly exposed to xylazine.
Not a fit: Patients who do not use fentanyl or are not at risk of overdose from these substances may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved safety measures and treatment protocols for patients affected by fentanyl and xylazine overdoses.
How similar studies have performed: While the specific combination of fentanyl and xylazine is relatively novel, previous research has shown significant risks associated with opioid and sedative co-administration.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Heerdt, Paul Mark — Yale University
- Study coordinator: Heerdt, Paul Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.